Shannon Hyslop1, L Lee Dupuis2, Christina Baggott3, David Dix4, Paul Gibson5, Susan Kuczynski6, Donna L Johnston7, Andrea Orsey8, Carol Portwine9, Vicky Price10, Brenda Spiegler11, Deborah Tomlinson1, Magimairajan Vanan12, George A Tomlinson13, Lillian Sung14. 1. Program in Child Health Evaluative Sciences, The Hospital for Sick Children, Peter Gilgan Centre for Research and Learning, Toronto, Ontario, Canada. 2. Program in Child Health Evaluative Sciences, The Hospital for Sick Children, Peter Gilgan Centre for Research and Learning, Toronto, Ontario, Canada; Department of Pharmacy, The Hospital for Sick Children, Toronto, Ontario, Canada; Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Ontario, Canada. 3. Pediatric Hematology/Oncology, Stanford University Cancer Clinical Trials Office, Palo Alto, California, USA. 4. Division of Hematology/Oncology/BMT, Department of Pediatrics, BC Children's Hospital, Vancouver, Canada. 5. Haematology/Oncology, Department of Pediatrics, London Health Sciences Centre, London, Ontario, Canada. 6. Ontario Parents Advocating for Children with Cancer (OPACC), Toronto, Ontario, Canada. 7. Division of Hematology/Oncology, Children's Hospital of Eastern Ontario, Ottawa, Ontario, Canada. 8. Division of Pediatric Hematology/Oncology, Connecticut Children's Medical Center, Hartford, Connecticut, USA. 9. Division of Haematology/Oncology, McMaster Children's Hospital, Health Sciences Centre, Hamilton, Ontario, Canada. 10. Division of Pediatric Hematology/Oncology, Department of Pediatrics, IWK Health Centre, Halifax, Nova Scotia, Canada. 11. Department of Psychology, The Hospital for Sick Children, Toronto, Ontario, Canada. 12. Departments of Pediatrics & Child Health and Biochemistry & Medical Genetics, Pediatric Hematology/Oncology/BMT, CancerCare Manitoba, Research Institute in Oncology and Hematology, University of Manitoba, Winnipeg, Manitoba, Canada. 13. Department of Medicine, Toronto General Hospital, Toronto, Ontario, Canada. 14. Program in Child Health Evaluative Sciences, The Hospital for Sick Children, Peter Gilgan Centre for Research and Learning, Toronto, Ontario, Canada; Division of Haematology/Oncology, The Hospital for Sick Children, Toronto, Ontario, Canada. Electronic address: lillian.sung@sickkids.ca.
Abstract
OBJECTIVES: Primary objectives were to evaluate the interrater reliability and validity of proxy-report Symptom Screening in Pediatrics Tool (SSPedi) in children with cancer and pediatric hematopoietic stem cell transplant (HSCT) recipients. Secondary objective was to describe the interrater reliability of each SSPedi item. METHODS: Respondents were children aged eight to 18 years with cancer or HSCT recipients, and their parents or guardians. We enrolled two pediatric respondent groups. The more symptomatic group was receiving active treatment for cancer, admitted to hospital, and expected to be in a hospital three days later. The less symptomatic group either was in maintenance therapy for acute lymphoblastic leukemia or had completed cancer treatments. Convergent validity was evaluated by comparing proxy-reported mucositis, nausea and vomiting, pain, and total SSPedi scores, with child self-reported validated scales, and we hypothesized fair correlations. Discriminant validity was evaluated by comparing proxy-reported total SSPedi scores between groups. Interrater reliability of each SSPedi item was evaluated. RESULTS: Four hundred thirty-nine child and parent or guardian pairs were recruited. Mean difference in proxy-reported SSPedi scores between the more and less symptomatic groups was 8.2, 95% CI 6.6-9.8. All hypothesized relationships among measures were observed. Intraclass correlation coefficients for SSPedi items ranged from 0.34 (problems with thinking) to 0.80 (diarrhea). CONCLUSION: Proxy-report SSPedi is reliable and valid in children aged 8 years to 18 years with cancer and HSCT recipients. Future work should support proxy-reported symptom assessment in clinical settings where children are not able to self-report or communicate bothersome symptoms.
OBJECTIVES: Primary objectives were to evaluate the interrater reliability and validity of proxy-report Symptom Screening in Pediatrics Tool (SSPedi) in children with cancer and pediatric hematopoietic stem cell transplant (HSCT) recipients. Secondary objective was to describe the interrater reliability of each SSPedi item. METHODS: Respondents were children aged eight to 18 years with cancer or HSCT recipients, and their parents or guardians. We enrolled two pediatric respondent groups. The more symptomatic group was receiving active treatment for cancer, admitted to hospital, and expected to be in a hospital three days later. The less symptomatic group either was in maintenance therapy for acute lymphoblastic leukemia or had completed cancer treatments. Convergent validity was evaluated by comparing proxy-reported mucositis, nausea and vomiting, pain, and total SSPedi scores, with child self-reported validated scales, and we hypothesized fair correlations. Discriminant validity was evaluated by comparing proxy-reported total SSPedi scores between groups. Interrater reliability of each SSPedi item was evaluated. RESULTS: Four hundred thirty-nine child and parent or guardian pairs were recruited. Mean difference in proxy-reported SSPedi scores between the more and less symptomatic groups was 8.2, 95% CI 6.6-9.8. All hypothesized relationships among measures were observed. Intraclass correlation coefficients for SSPedi items ranged from 0.34 (problems with thinking) to 0.80 (diarrhea). CONCLUSION: Proxy-report SSPedi is reliable and valid in children aged 8 years to 18 years with cancer and HSCT recipients. Future work should support proxy-reported symptom assessment in clinical settings where children are not able to self-report or communicate bothersome symptoms.
Authors: Robyn Loves; Deborah Tomlinson; Christina Baggott; David Dix; Paul Gibson; Shannon Hyslop; Donna L Johnston; Andrea D Orsey; Carol Portwine; Victoria Price; Tal Schechter; Magimairajan Vanan; Susan Kuczynski; Brenda Spiegler; George A Tomlinson; L Lee Dupuis; Lillian Sung Journal: Support Care Cancer Date: 2018-10-15 Impact factor: 3.603
Authors: Deborah Tomlinson; L Lee Dupuis; Donna L Johnston; Susan Kuczynski; Serina Patel; Tal Schechter; Emily Vettese; Mark Mairs; George A Tomlinson; Lillian Sung Journal: BMC Cancer Date: 2022-07-04 Impact factor: 4.638
Authors: Sadie Cook; Emily Vettese; Dilip Soman; Shannon Hyslop; Susan Kuczynski; Brenda Spiegler; Hailey Davis; Nathan Duong; Stacee Ou Wai; Robert Golabek; Patryk Golabek; Adam Antoszek-Rallo; Tal Schechter; L Lee Dupuis; Lillian Sung Journal: BMC Med Inform Decis Mak Date: 2019-01-10 Impact factor: 2.796
Authors: E Anne Lown; Anu Banerjee; Eric Vittinghoff; Christopher C Dvorak; Wendy Hartogensis; Alexis Melton; Christina Mangurian; Hiroe Hu; Deborah Shear; Robyn Adcock; Michael Morgan; Carla Golden; Frederick M Hecht Journal: Glob Adv Health Med Date: 2019-08-14
Authors: Cody Z Watling; Clodagh McCarthy; Alexandra Theodorakidis; Sadie Cook; Emily Vettese; Tal Schechter; Hanan Abubeker; L Lee Dupuis; Lillian Sung Journal: BMC Cancer Date: 2020-09-25 Impact factor: 4.430